Latest Articles

Publication Date
ASCO Reading Room | Is the End of Systemic Chemotherapy Near for Advanced Endometrial Cancer? - Medpage Today

ASCO Reading Room | Is the End of Systemic Chemotherapy Near for Advanced Endometrial Cancer? Medpage Today

Published: Feb. 5, 2025, 7:31 p.m.
Christian Marth on a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer - Medpage Today

Christian Marth on a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer Medpage Today

Published: Feb. 5, 2025, 5:54 p.m.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial - Medpage Today

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial Medpage Today

Published: Feb. 5, 2025, 5:54 p.m.
Azurocidin is Associated with Dienogest-resistance in Ovarian Endometriotic Cysts.

Endometriosis and ovarian endometrioma (OMA) cause dysmenorrhea and infertility. Current hormonal therapies for OMA treatment, may exhibit limited effectiveness. Hormonal treatments function by downregulate estrogen receptors (ERs) via progesterone receptor …

Published: Feb. 5, 2025, midnight
(PDF) Radiotherapy improves stress urinary incontinence but impairs pelvic floor function in endometrial cancer patients: a prospective cohort study - ResearchGate

(PDF) Radiotherapy improves stress urinary incontinence but impairs pelvic floor function in endometrial cancer patients: a prospective cohort study ResearchGate

Published: Feb. 2, 2025, 4:08 a.m.
Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women.

Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …

Published: Feb. 1, 2025, midnight
The NLRP3 activation-related signature predicts the diagnosis and indicates immune characteristics in endometriosis.

Endometriosis (EMS) is a prevalent gynecological disease that leads to chronic pelvic pain and infertility in women of reproductive age. However, the underlying pathogenic genes and effective treatment for EMS …

Published: Jan. 31, 2025, midnight
Eligibility criteria for the use menopausal hormone therapy (MHT) in women with medical conditions (II): Endometriosis, neurological and autoimmune diseases.

This project developed eligibility criteria for menopausal hormone therapy in patients with medical conditions beyond those published in a previous report. A new consortium of scientific societies coordinated by the …

Published: Jan. 30, 2025, midnight
Rare malignant ovarian tumors: a review.

There are many histologic types of gynecologic malignancies. I reviewed three rare ovarian tumor types that have poor prognoses. Ovarian mesonephric-like adenocarcinoma (MLA) is a newly described histological type known …

Published: Jan. 29, 2025, midnight
Editorial: Advances in the pharmacotherapy of chronic pelvic pain conditions.

Published: Jan. 29, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!